

# Malaria: Vaccine clinical trial for pregnant women yields promising results

February 5 2020

---



Credit: CC0 Public Domain

Malaria infection during pregnancy represents a major public health problem in the regions endemic for the disease, substantially increasing the risks to mothers and their unborn children. A new vaccine known as

PRIMVAC has undergone a clinical trial to study its safety and collect preliminary data on its ability to induce an immune response.

According to the World Health Organization, malaria is responsible for over 400,000 deaths each year. Despite the progress made in fighting the disease in recent decades, some populations remain particularly vulnerable. One such population is pregnant women.

In the areas of the world where malaria is endemic, people acquire immunity throughout their childhood, meaning that they are generally protected against its most severe outcomes once they reach adulthood. However, pregnant women are an exception because the [red blood cells](#) infected with the Plasmodium falciparum parasite responsible for malaria accumulate in the placenta, promoting anemia and gestational hypertension. The disease is also linked to a higher risk of spontaneous abortion, [premature birth](#) and intrauterine growth delays which lead to low birth weight and a high rate of neonatal mortality. In Sub-Saharan Africa, 11 million pregnant women were infected with malaria in 2018, with around 900,000 of their babies born underweight.

To tackle this public health problem, a team of researchers from Inserm and Université de Paris led by CNRS Research Director Benoît Gamain has spent the past two decades developing a vaccine for gestational malaria. The goal is to prevent the deaths of up to 10,000 mothers and 200,000 babies each year. "Developing an effective vaccine for young women before their first pregnancy is a priority if we are to reduce malaria-related mortality. An [effective strategy](#) could focus on a population similar to that targeted by HPV vaccination, for example, before the women become sexually active," emphasizes Benoît Gamain.

## **A safe and effective vaccine**

Called PRIMVAC, the vaccine had recently been produced in large

quantities in accordance with current regulations. In a clinical trial published in *Lancet Infectious Diseases*, the researchers provide data on its safety and ability to induce an appropriate immune response, up to 15 months after the initial vaccination.

The vaccine was evaluated in 68 non-[pregnant women](#) aged 18 to 35 at the Cochin Pasteur Clinical Investigation Center in Paris, then at the National Center for Research and Training on Malaria (CNRFP) in Ouagadougou, Burkina Faso. The participants were randomly assigned to four cohorts, receiving the vaccine at various doses, on three occasions over a period of three months. These women were then monitored for 15 months in order to identify and treat any side effects and study the immune response induced by the vaccination.

The results of this study show that PRIMVAC is well tolerated. In addition, the researchers have shown that vaccine can produce an immune response, with the production of antibodies in 100% of women vaccinated after only two injections. The antibodies produced are capable of both recognizing the parasitic antigen on the surface of the infected red blood cells and inhibiting their adhesive capacity, which is responsible for their accumulation in the placenta.

"We were able to show that the vaccine is well tolerated, at all the tested doses. The side effects observed were mainly pain at the injection site. We also revealed that the quantity of antibodies generated by the vaccine increases after each vaccination and that they persist for several months. It therefore appears that the [vaccine](#) has the capacity to trigger a lasting and potentially protective immune response," underlines Gamain.

Studying this immune response on the longer term will be the subject of future [clinical trials](#). The researchers want to continue monitoring the 50 Burkinabe volunteers in order to evaluate whether the [immune response](#) induced by the vaccination is maintained until their first pregnancy.

**More information:** Sodiomon B Sirima et al, PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study, *The Lancet Infectious Diseases* (2020). [DOI: 10.1016/S1473-3099\(19\)30739-X](https://doi.org/10.1016/S1473-3099(19)30739-X)

Provided by Institut National de la Sante et de la Recherche Medicale

Citation: Malaria: Vaccine clinical trial for pregnant women yields promising results (2020, February 5) retrieved 27 April 2024 from <https://medicalxpress.com/news/2020-02-malaria-vaccine-clinical-trial-pregnant.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.